Real-world use of biologics for non-systemic juvenile idiopathic arthritis: Information from a Japanese hospital claims database.

IF 2.1 4区医学 Q3 RHEUMATOLOGY

Modern Rheumatology Pub Date : 2026-08-31 DOI:10.1093/mr/roag025

Takashi Funatogawa, Kazuma Mii, Saki Katayama, Yuka Aoki, Yasuaki Matsubara, Kazuki Kojima, Mariko Hoshiba

{"title":"Real-world use of biologics for non-systemic juvenile idiopathic arthritis: Information from a Japanese hospital claims database.","authors":"Takashi Funatogawa, Kazuma Mii, Saki Katayama, Yuka Aoki, Yasuaki Matsubara, Kazuki Kojima, Mariko Hoshiba","doi":"10.1093/mr/roag025","DOIUrl":null,"url":null,"abstract":"Objectives: Limited information is available on patients with non-systemic juvenile idiopathic arthritis (nsJIA) receiving biologics in Japan. The types of biologics, treatment duration, prior and concomitant treatments, administration routes (intravenous [IV] or subcutaneous [SC] injection), and patient characteristics were investigated.Methods: We investigated nsJIA, excluding psoriatic arthritis and ankylosing spondylitis, using data from a Japanese hospital claims database (2008-2024).Results: Of the 4191 nsJIA patients in the database, 965 (23.0%) received one or more biologics. For the first biologic, the most common were antitumour necrosis factor (anti-TNF) drugs (55.3% overall; adalimumab SC, 32.1%; etanercept SC, 9.8%; infliximab IV, 9.2%; others, < 2.1% each), followed by anti-interleukin-6 (anti-IL-6) drugs (39.9% overall; tocilizumab, 39.1% [IV, 32.4%; SC, 6.6%]; others, ≤ 0.7%), abatacept IV or SC (3.7%), and canakinumab SC (1.0%). Of the patients receiving anti-TNF and anti-IL-6 drugs, 40% and 58% continued treatment for ≥1 year, respectively. The most common conventional synthetic disease-modifying antirheumatic drug (csDMARD) administered prior to anti-TNF and anti-IL-6 drugs was methotrexate [39.0% (anti-TNF) and 33.5% (anti-IL-6)], with others at ≤ 3.6%. The most common csDMARD used concomitantly was also methotrexate [66.9% (anti-TNF) and 50.4% (anti-IL-6)], with others < 8.6%.Conclusions: Our study describes the real-world usage of biologics for nsJIA in Japan.","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":" ","pages":"826-836"},"PeriodicalIF":2.1000,"publicationDate":"2026-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Modern Rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/mr/roag025","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: Limited information is available on patients with non-systemic juvenile idiopathic arthritis (nsJIA) receiving biologics in Japan. The types of biologics, treatment duration, prior and concomitant treatments, administration routes (intravenous [IV] or subcutaneous [SC] injection), and patient characteristics were investigated.

Methods: We investigated nsJIA, excluding psoriatic arthritis and ankylosing spondylitis, using data from a Japanese hospital claims database (2008-2024).

Results: Of the 4191 nsJIA patients in the database, 965 (23.0%) received one or more biologics. For the first biologic, the most common were antitumour necrosis factor (anti-TNF) drugs (55.3% overall; adalimumab SC, 32.1%; etanercept SC, 9.8%; infliximab IV, 9.2%; others, < 2.1% each), followed by anti-interleukin-6 (anti-IL-6) drugs (39.9% overall; tocilizumab, 39.1% [IV, 32.4%; SC, 6.6%]; others, ≤ 0.7%), abatacept IV or SC (3.7%), and canakinumab SC (1.0%). Of the patients receiving anti-TNF and anti-IL-6 drugs, 40% and 58% continued treatment for ≥1 year, respectively. The most common conventional synthetic disease-modifying antirheumatic drug (csDMARD) administered prior to anti-TNF and anti-IL-6 drugs was methotrexate [39.0% (anti-TNF) and 33.5% (anti-IL-6)], with others at ≤ 3.6%. The most common csDMARD used concomitantly was also methotrexate [66.9% (anti-TNF) and 50.4% (anti-IL-6)], with others < 8.6%.

Conclusions: Our study describes the real-world usage of biologics for nsJIA in Japan.

查看原文本刊更多论文

真实世界中使用生物制剂治疗非系统性青少年特发性关节炎：来自日本医院索赔数据库的信息。

目的：关于日本非系统性青少年特发性关节炎（nsJIA）患者接受生物制剂的信息有限。研究了生物制剂的类型、治疗时间、既往和伴随治疗、给药途径（静脉注射或皮下注射）和患者特征。方法：我们调查nsJIA，排除银屑病关节炎和强直性脊柱炎，使用日本医院索赔数据库（2008-2024）的数据。结果：在数据库中的4191例nsJIA患者中，965例（23.0%）接受了一种或多种生物制剂。对于第一种生物制剂，最常见的是抗肿瘤坏死因子（anti-TNF）药物（55.3%），阿达木单抗SC， 32.1%，依那西普SC， 9.8%，英夫利昔单抗IV， 9.2%，其他。结论：我们的研究描述了日本生物制剂治疗nsJIA的实际使用情况。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Modern Rheumatology RHEUMATOLOGY-

CiteScore

4.90

自引率

9.10%

发文量

146

审稿时长

1.5 months

期刊介绍： Modern Rheumatology publishes original papers in English on research pertinent to rheumatology and associated areas such as pathology, physiology, clinical immunology, microbiology, biochemistry, experimental animal models, pharmacology, and orthopedic surgery. Occasional reviews of topics which may be of wide interest to the readership will be accepted. In addition, concise papers of special scientific importance that represent definitive and original studies will be considered. Modern Rheumatology is currently indexed in Science Citation Index Expanded (SciSearch), Journal Citation Reports/Science Edition, PubMed/Medline, SCOPUS, EMBASE, Chemical Abstracts Service (CAS), Google Scholar, EBSCO, CSA, Academic OneFile, Current Abstracts, Elsevier Biobase, Gale, Health Reference Center Academic, OCLC, SCImago, Summon by Serial Solutions